Point/counterpoint: Early-stage Hodgkin lymphoma and the role of radiation therapy

Blood

Volumn 120, Issue 23, 2012, Pages 4488-4495

  Meyer, Ralph M ^a,b   Hoppe, Richard T ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); EVENT FREE SURVIVAL; HEART DISEASE; HODGKIN DISEASE; HUMAN; LYMPH NODE IRRADIATION; MEDICAL SPECIALIST; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RADIATION DOSE; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

EID: 84870522296     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-423236     Document Type: Review

References (57)

1. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-652.
2. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366(5):399-408.
3. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma. J Natl Compr Canc Netw. 2011;9(9): 1020-1058.
4. Pusey WA. Cases of sarcoma and of Hodgkin's disease treated by exposure to X-rays: a preliminary report. JAMA. 1902;38:166-169.
5. Gilbert R. Notre Methode De Roentgentherapie De La Lymphogranulomatose (Hodgkin): Resultats Eloignes. Acta Radiol. 1931;12.
6. Peters M.Astudy of survival in Hodgkin's disease treated radiologically. AJRAm J Roentgenol. 1950;63:299-311.
7. Kaplan HS. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology. 1962;78:553-561.
8. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman AZ, McLennan MT. Nitrogen mustard therapy: use of methyl-bis (betachloroethyl) amine hydrochloride and tris (betachloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 1946;132:126-132.
9. Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73(6):881-895.
10. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36(1):252-259.
11. NgAK, Mauch PM. Late effects of Hodgkin's disease and its treatment. Cancer J. 2009;15(2):164-168.
12. Carde P, Burgers JM, Henry-Amar M, et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol. 1988;6(2):239-252. (Pubitemid 18068598)
13. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993;11(11):2258-2272. (Pubitemid 23332265)
14. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001;19(22):4238-4244. (Pubitemid 33081641)
15. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25(23):3495-3502. (Pubitemid 47310889)
16. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007;357(19):1916- 1927. (Pubitemid 350074687)
17. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004;22(14):2835-2841. (Pubitemid 41079901)
18. Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst. 1988;80(18):1466-1473. (Pubitemid 18264890)
19. Longo DL, Glatstein E, Duffey PL, et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol. 1991;9(6):906-917.
20. Biti GP, Cimino G, Cartoni C, et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. J Clin Oncol. 1992;10(3):378-382.
21. Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose level) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's Lymphoma (HL). J Clin Oncol. 2005;23.
22. Herbst C, Rehan FA, Brillant C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica. 2010;95(3):494-500.
23. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199-4206.
24. Advani R, Hoppe RT, Baer DM, Mason J, Rosenberg SA, Horning SJ. Efficacy of abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: mature results of the G4 trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:1670.
25. Gordon L, Hong F, Fisher RI. A randomized phase III trial of ABVD vs Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Lymphoma: an Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:415.
26. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol. 2004;22(1):62-68. (Pubitemid 41095115)
27. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104(12):3483-3489. (Pubitemid 39564416)
28. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20(18):3765-3771.
29. Gospodarowicz MK, Meyer RM. The management of patients with limited-stage classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2006;2006:253-258.
30. Eichenauer DA, Engert A, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi55-vi58.
31. Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005;16(10):1683-1687. (Pubitemid 41510144)
32. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(21):4634-4642. (Pubitemid 46237440)
33. Rosenberg SA, Kaplan HS. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys. 1985;11(1):5-22. (Pubitemid 15169347)
34. Hoppe R, Abrams R, Bernstein S, et al. NCCN Practice Guidelines for Hodgkin's Disease Oncology. 1999;13:78-110. (Pubitemid 29269202)
35. Koh ES, Tran TH, Heydarian M, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol. 2007;2:13.
36. De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27(26):4239-4246.
37. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993;270(16):1949- 1955. (Pubitemid 23312611)
38. Campbell BA, Voss N, Pickles T, et al. Involvednodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol. 2008;26(32):5170-5174.
39. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79(3):270-277. (Pubitemid 44109907)
40. Maraldo MV, Brodin NP, Vogelius IR, et al. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;83(4):1232-1237.
41. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206-214.
42. Connors JM. Positron emission tomography in the management of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:317-322.
43. Lemmens T, Singer PA. Bioethics for clinicians: 17. Conflict of interest in research, education and patient care. CMAJ. 1998;159(8):960-965.
44. Meyer RM, Ambinder RF, Stroobants S. Hodgkin's lymphoma: evolving concepts with implications for practice. Hematology Am Soc Hematol Educ Program. 2004;2004:184-202.
45. Zittoun R, Audebert A, Hoerni B, et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol. 1985;3(2):207-214. (Pubitemid 15153762)
46. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003;21(19):3601-3608. (Pubitemid 46594052)
47. Meyer RM. Generalizing the results of cancer clinical trials. J Clin Oncol. 2010;28(2):187-189.
48. Eich HT, Engenhart-Cabillic R, Hansemann K, et al. Quality control of involved field radiotherapy in patients with early-favorable (HD10) and earlyunfavorable (HD11) Hodgkin's lymphoma: an analysis of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys. 2008;71(5):1419-1424.
49. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med. 2002;137(6):511-520. (Pubitemid 35024623)
50. Smitt MC, Stouffer N, Owen JB, Hoppe RT, Hanks GE. Results of the 1988-1989 Patterns of Care Study process survey for Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1999;43(2):335-339. (Pubitemid 29091473)
51. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol. 2000;18(11):2327-2340. (Pubitemid 30350226)
52. Peters LJ, O'Sullivan B, Giralt J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol. 2010;28(18):2996-3001.
53. Sackett DL. Bias in analytic research. J Chronic Dis. 1979;32(1):51-63.
54. Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P. Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Ann Intern Med. 2011;155(1):39-51.
55. Tipton K, Launders JH, Inamdar R, Miyamoto C, Schoelles K. Stereotactic body radiation therapy: scope of the literature. Ann Intern Med. 2011;154(11):737-745.
56. Chera BS, Rodriguez C, Morris CG, et al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and threedimensional proton radiotherapy. Int J Radiat Oncol Biol Phys. 2009;75(4):1173-1180.
57. Quill TE, Holloway RG. Evidence, preferences, recommendations: finding the right balance in patient care. N Engl J Med. 2012;366(18):1653-1655.